| Fenebrutinib for treating primary progressive multiple sclerosis [ID6543] | Technology appraisal guidance |
| Fenebrutinib for treating relapsing multiple sclerosis [ID6577] | Technology appraisal guidance |
| Filgotinib for Axial spondyloarthritis [ID12209] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Galcanezumab for migraine [TSID10663] | Technology appraisal guidance |
| Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126] | Technology appraisal guidance |
| Gantenerumab for treating early Alzheimer's disease [TSID10668] | Technology appraisal guidance |
| Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 inhibitor and endocrine treatment [ID6576] | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071] | Technology appraisal guidance |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747] | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579] | Technology appraisal guidance |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies [ID6491] | Technology appraisal guidance |
| Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376] | Technology appraisal guidance |
| In-situ Normothermic Regional Perfusion system for DCD donors - liver | Interventional procedures guidance |
| Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over
[ID6551] | Technology appraisal guidance |
| Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129] | Technology appraisal guidance |
| Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430] | Technology appraisal guidance |
| Inebilizumab for treating generalised myasthenia gravis
[TSID12110] | Technology appraisal guidance |
| Inebilizumab for treating immunoglobulin G4-related disease
[TSID12107] | Technology appraisal guidance |
| Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923] | Technology appraisal guidance |